Guggenheim analyst Yastin Suneja raised the firm’s price target on Roivant Sciences (ROIV) to $25 from $21 and keeps a Buy rating on the shares after updating the firm’s model to reflect current spend rates and pipeline updates following the company’s Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences Reports Q2 2025 Financial Results
- Roivant Sciences price target raised to $26 from $25 at Citi
- Promising Developments and Strong Financial Position Justify Buy Rating for Roivant Sciences
- Roivant Sciences reports Q2 EPS (17c), consensus (30c)
- Roivant Sciences sees cash runway into profitability